In prostate cancer Clovis could be adopting a more realistic regulatory stance with its Parp than Astrazeneca and Merck & Co. In the long run will it matter much?
Lynparza looks set to add a third tumour type to its label, strengthening the grip of Astrazeneca and Merck & Co on the Parp inhibitor market.
The Prima trial delivers a convincing win for Glaxosmithkline’s Parp inhibitor Zejula, which looks to have a good chance of winning a broader label in ovarian cancer.
Abbvie has finally scored a win with its Parp inhibitor, but the product will struggle to make headway – assuming it will even be filed.
The Paola-1 study of Astrazeneca and Merck & Co’s Lynparza plus Avastin shows that more ovarian cancer patients can benefit from Parp inhibition, though the role of…
The beleaguered drug maker has licensed a preclinical FAP-directed radiopharmaceutical, a target that has made little progress.
Success for Lynparza in first-line ovarian cancer, regardless of BRCA mutation status, could see Astrazeneca’s drug regain the upper hand against Glaxosmithkline’s…
As Lynparza threatens Rubraca in prostate cancer, investors should now focus on whether Astra will show a benefit in the ATM-mutant patient population.
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.